This study was a randomized, double-blind, placebo-controlled trial conducted in Thailand. It involved patients with nasopharyngeal carcinoma who were undergoing concurrent chemoradiotherapy. Half of the patients received 2 grams of intravenous vitamin C before their chemotherapy sessions, while the other half received a placebo. The main goal was to see if vitamin C could reduce side effects and protect blood cells.
The researchers found that the vitamin C group did not have fewer gastrointestinal problems compared to the placebo group. Issues like nausea, loss of appetite, mouth sores, diarrhea, and swallowing difficulties occurred at similar rates in both groups. However, the vitamin C group showed a significantly slower decline in platelet counts compared to those who received the placebo. This suggests the vitamin might help maintain platelet levels during treatment.
There were no specific safety concerns or serious adverse events reported that required stopping the study. The main reason to be careful is that this study was limited to one type of cancer and one specific setting. Readers should understand that while platelet preservation looks helpful, the overall benefits of intravenous vitamin C for this condition are not yet fully proven and warrant further investigation.